Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0011853
Disease: Diabetes Mellitus, Experimental
Diabetes Mellitus, Experimental
0.500 Biomarker disease CTD_human Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1α axis in db/db mice. 23090186 2013
CUI: C0021655
Disease: Insulin Resistance
Insulin Resistance
0.500 Biomarker phenotype CTD_human Impact of dietary fat quantity and quality on skeletal muscle fatty acid metabolism in subjects with the metabolic syndrome. 22658938 2012
CUI: C0011853
Disease: Diabetes Mellitus, Experimental
Diabetes Mellitus, Experimental
0.500 Biomarker disease RGD In vivo and in vitro effects of SREBP-1 on diabetic renal tubular lipid accumulation and RNAi-mediated gene silencing study. 19048273 2009
CUI: C0021655
Disease: Insulin Resistance
Insulin Resistance
0.500 Biomarker phenotype RGD Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. 17241878 2007
CUI: C0011853
Disease: Diabetes Mellitus, Experimental
Diabetes Mellitus, Experimental
0.500 Biomarker disease CTD_human Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. 10900012 2000
Diabetes Mellitus, Non-Insulin-Dependent
0.400 PosttranslationalModification disease BEFREE Critical evaluation of the DNA-methylation markers ABCG1 and SREBF1 for Type 2 diabetes stratification. 31169416 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE In conclusion, these results indicated that emodin could induce apoptosis in an SREBP1-dependent and SREBP1-independent manner in hepatocellular carcinoma cells. 31297058 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE And the inhibitor of SREBP1 and mTOR may help to prevent HCC in clinical NAFLD patients. 31409773 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE This observation suggested the negative role of SREBP-1 in clinical HCC prognosis. 31511501 2019
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.400 Biomarker disease BEFREE In conclusion, dietary BA enhanced the growth and alleviated liver fibrosis induced by a high starch diet to steatohepatitis/recovery symptom via improving glucose and lipid metabolism, which regulated by AKT/FOXO1 and cAMP/AMPK/SREBP1 pathway in largemouth bass. 31824338 2019
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.400 Biomarker disease BEFREE Our study unveils an H19/PTBP1/sterol regulatory element-binding protein 1 feedforward amplifying signaling pathway to exacerbate the development of fatty liver.(Hepatology 2018;67:1768-1783). 29140550 2018
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.400 AlteredExpression disease BEFREE Loss of Pgrmc1 increased mature SREBP-1 protein level, suggesting that induction of hepatic steatosis in Pgrmc1 KO mice might be triggered by de novo lipogenesis. 30356113 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Taken together, these data suggest that HSWE induces an intrinsic apoptosis, and reduced unsaturated fatty acids by blocking SREBP1 in hepatocellular carcinoma cells. 29702135 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 AlteredExpression disease BEFREE Coexpression of SREBP-1 and nuclear HDGF predicts poor prognosis for HCC. 30004626 2018
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.400 AlteredExpression disease BEFREE Loss of Pgrmc1 increased mature SREBP-1 protein level, suggesting that induction of hepatic steatosis in Pgrmc1 KO mice might be triggered by de novo lipogenesis. 30356113 2018
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.400 Biomarker disease BEFREE Our study unveils an H19/PTBP1/sterol regulatory element-binding protein 1 feedforward amplifying signaling pathway to exacerbate the development of fatty liver.(Hepatology 2018;67:1768-1783). 29140550 2018
Diabetes Mellitus, Non-Insulin-Dependent
0.400 GeneticVariation disease BEFREE <b>Results</b>: Both SREBPs mRNA expression were significantly higher in patients with CAD and diabetes (p<0.001) and were identified as independent cardiovascular risk factor for coronary artery disease in patients with type-2 diabetes (SREBP-1: OR 1.7, 95%CI 1.1-2.5, p=0.02; SREBP-2: OR 1.6, 95%CI 1.2-3, p=0.02) and were independently associated with the presence of multivessel CAD, left main and anterior descending artery stenosis, and higher total and LDL cholesterol levels, and lower HDL cholesterol levels, in patients with CAD and diabetes. 28367087 2017
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.400 Biomarker disease BEFREE FK866 significantly promoted liver steatosis in the mice fed with HFD and hepatic lipid accumulation in vitro, accompanied by the increases of the expressions of lipogenic genes such as sterol regulatory element-binding protein 1 (SREBP1) and fatty acid synthase (FASN). 28449683 2017
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.400 Biomarker disease BEFREE The improvement of hepatic steatosis observed in DIO-treated mice was associated with a decrease in the hepatic content of SREBP-1, a transcription factor involved in de novo lipogenesis. 28557705 2017
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.400 Biomarker disease BEFREE Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease. 28483554 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Clinically, our data revealed that TIP30 expression significantly correlated with SREBP1 in patients with HCC and that a combination of TIP30 and SREBP1 is a powerful predictor of HCC prognosis. 28604762 2017
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.400 Biomarker disease BEFREE The improvement of hepatic steatosis observed in DIO-treated mice was associated with a decrease in the hepatic content of SREBP-1, a transcription factor involved in de novo lipogenesis. 28557705 2017
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.400 Biomarker disease BEFREE Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease. 28483554 2017
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.400 Biomarker disease BEFREE FK866 significantly promoted liver steatosis in the mice fed with HFD and hepatic lipid accumulation in vitro, accompanied by the increases of the expressions of lipogenic genes such as sterol regulatory element-binding protein 1 (SREBP1) and fatty acid synthase (FASN). 28449683 2017
Diabetes Mellitus, Non-Insulin-Dependent
0.400 GeneticVariation disease BEFREE DNA methylation of cg18181703 (SOCS3), cg11024682 (SREBF1), and cg19693031 (TXNIP) was not associated with future T2D risk in subjects from the Botnia prospective study. 27148772 2016